Form 8-K - Current report:
SEC Accession No. 0001437749-24-038020
Filing Date
2024-12-20
Accepted
2024-12-20 07:05:21
Documents
15
Period of Report
2024-12-19
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K eton20241215_8k.htm   iXBRL 8-K 28197
2 EXHIBIT 99.1 PRESS RELEASE RELATING TO ET-400 FILING ex_757680.htm EX-99.1 27463
  Complete submission text file 0001437749-24-038020.txt   195282

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eton-20241219.xsd EX-101.SCH 3411
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE eton-20241219_def.xml EX-101.DEF 11426
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE eton-20241219_lab.xml EX-101.LAB 15312
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eton-20241219_pre.xml EX-101.PRE 11586
17 EXTRACTED XBRL INSTANCE DOCUMENT eton20241215_8k_htm.xml XML 2845
Mailing Address 21925 W. FIELD PARKWAY SUITE 235 DEER PARK IL 60010-7278
Business Address 21925 W. FIELD PARKWAY SUITE 235 DEER PARK IL 60010-7278 (847) 787-7361
Eton Pharmaceuticals, Inc. (Filer) CIK: 0001710340 (see all company filings)

EIN.: 371858472 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38738 | Film No.: 241565090
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)